MAP2K7 and neoplasm: MEK/Erk and PI3K/Akt could also be activated by different growth factors, such as EGFR and ErbB3 [45–47], thus tumor types and stages, as well as CD44 isoforms and expression levels should be considered when these inhibitors are combined with chemotherapy for PDAC treatment.